News
-
-
-
-
-
-
-
-
-
-
PRESS RELEASE
TuHURA Biosciences and Kintara Therapeutics Announce Kineta Inc. Reopens Enrollment for VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer
Kineta reopens enrollment for VISTA-101 clinical trial with KVA12123 antibody. Positive results at AACR 2024. TuHURA and Kineta join forces. Acquisition pending. Kintara merger progresses